Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Oct 10, 2014; 5(4): 560-567
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.560
Published online Oct 10, 2014. doi: 10.5306/wjco.v5.i4.560
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Kevin Becker, Yiqing Xu, Division of Hematology and Oncology, Maimonides Cancer Center, Brooklyn, NY 11201, United States
Author contributions: Becker K and Xu Y wrote the paper.
Correspondence to: Kevin Becker, MD, Division of Hematology and Oncology, Maimonides Cancer Center, 6300 Eighth Ave, Brooklyn, NY 11201, United States. kbecker@maimonidesmed.org
Telephone: +1-718-7652613 Fax: +1-718-7652630
Received: December 29, 2013
Revised: March 22, 2014
Accepted: June 20, 2014
Published online: October 10, 2014
Processing time: 215 Days and 14.6 Hours
Revised: March 22, 2014
Accepted: June 20, 2014
Published online: October 10, 2014
Processing time: 215 Days and 14.6 Hours
Core Tip
Core tip: The causes of epidermal growth factor receptor tyrosine kinase inhibitor (TKI) treatment failure including pharmacokinetic failure, intrinsic resistance and acquired resistance are discussed. We review the molecular mechanisms of resistance and the options for clinical management of disease progression. Promising investigational strategies for overcoming TKI resistance are highlighted.